This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.

Celgene files reply in support of injunction against Nimbus Therapeutics regarding psoriasis drug

( October 5, 2021, 22:31 GMT | Official Statement) -- MLex Summary: Celgene told a US judge that without an injunction against Nimbus Therapeutics it will suffer irreparable harm because the right to assign a Tyrosine-Kinase 2 inhibitor product that is five years away from being market ready will be difficult to value and Nimbus may argue that the attendant damages should be severely limited. “Indeed, it is for these reasons that in the Warrant the parties expressly agreed that irreparable harm will occur if the parties do not honor the terms of the Warrant. Nimbus should not be able to evade its obligations by claiming the Warrant’s deadlines are continuing to run or by selling or encumbering the asset before a judgment is issued,” it said in a reply brief in support of a preliminary injunction....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections